https://www.selleckchem.com/products/sw-100.html
Patients in whom the post-NAC PNI can be improved have a high probability of obtaining a good prognosis. The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching
Curtir
Comentario
Compartilhar
